Breaking News, Collaborations & Alliances

Syneron Bio, AstraZeneca Partner to Develop Macrocyclic Peptides

Under the collaboration, AstraZeneca will gain access to Syneron's drug research & development platform.

Author Image

By: Charlie Sternberg

Associate Editor

Syneron Bio, an oral macrocyclic peptide drug biotech company, has partnered with AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of chronic diseases. Under this collaboration, AstraZeneca will gain access to Syneron Bio’s Synova platform, an intelligent and high-throughput macrocyclic peptide drug research and development platform designed to support the advancements of research programs exploring possible future treatments of chronic diseases, in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics